Envudeucitinib in Plaque Psoriasis: Long-Term Findings from STRIDE

STRIDE’s 52‑week extension shows envudeucitinib delivers durable skin clearance with a manageable safety profile, positioning it as a sustained oral option for adults with moderate‑to‑severe plaque psoriasis.

Across the cohort, substantial proportions of patients achieved and maintained PASI75 and PASI90 through one year, with overall tolerability consistent with earlier reports.

STRIDE enrolled adults with moderate‑to‑severe plaque psoriasis into an open‑label 52‑week extension to evaluate long‑term outcomes on envudeucitinib and track standard efficacy endpoints (PASI75, PASI90). The extension followed participants from the parent trials and captured durability endpoints, safety measures, and retention through week 52, using prespecified efficacy thresholds and routine laboratory and adverse‑event monitoring.

By week 52, most responders at earlier timepoints retained PASI75 and PASI90, and mean absolute PASI scores remained substantially reduced from baseline. Patients who reached PASI90 early generally kept that level of clearance through the extension, indicating a durable response pattern rather than a transient benefit.

Safety through week 52 was consistent with prior phase results. Adverse events were generally mild to moderate, most commonly including upper respiratory symptoms, headache, and mostly transient laboratory abnormalities. Serious adverse events were uncommon, discontinuations for adverse events were infrequent, and no new safety signals emerged compared with earlier phases, supporting tolerability with routine monitoring.

Envudeucitinib’s selective TYK2 inhibition targets cytokine pathways relevant to psoriasis pathogenesis, which plausibly underpins the observed efficacy and the manageable safety profile. Less selective JAK or TYK2/JAK inhibitors affect a broader range of kinases and carry different safety considerations; selectivity provides a mechanism‑driven rationale for differential tolerability but is not a claim of categorical superiority. Given its mechanism and the 52‑week data, envudeucitinib may fit alongside other oral agents for patients seeking sustained control.